Disruptive and Novel Therapeutics for Oncology Indications

20 Jan 2023
Patient and Clinical Considerations Track

9:00am Chair Introduction

Ana Rosa Sáez Ibáñez, Research Analyst, Cancer Research Institute 


9:05am Presentation: NK Cells Impacting Oncology Pipelines

  • Off-the-shelf is a minmum
  • Potency is crucial

Troels Jordansen, Chief Executive Officer, Glycostem Therapeutics


9:20am Presentation: TBC

Senior Representative, Tensentric


9:35am Presentation: TBA

Jeff Liter, Chief Executive Officer, Luminary TherapeuticsTroels Jordansen, Chief Executive Officer, Glycostem Therapeutics


9:50am Presentation: TBA

Allen Feng, Chief Scientific Officer, HebeCell


10:05am Closing Panel with Q&A

With all session participants


Ana Rosa Sáez Ibáñez
Research Analyst, Clinical Accelerator and Venture Fund
Cancer Research Institute
Jeff Liter
President and Chief Executive Officer
Luminary Therapeutics
Troels Jordansen
Chief Executive Officer
Allen Feng
Co-Founder and Chief Scientific Officer
HebeCell Corp